BACKGROUND:

Several nonclinical drug-development tools (DDTs) have been used for antituberculosis drug development over several decades. The role of the DDTs used for evaluating the efficacy of antituberculosis drug combinations and the gaps in the evidence base for which new tools or approaches are needed are as yet undefined.

METHODS:

We performed a landscape analysis based on a comprehensive literature review to create evidence based guidelines.

 

(후략)